The following clinical trials represent a selection of key studies that are currently recruiting patients with scleroderma for inclusion in investigations of new therapies and new regimens of existing treatments for individuals with the disease.
As of December 2017, 32 states and the District of Columbia have adopted USP 797 into law, including New Hampshire. Once adopted, a state agency, which is typically the state’s Board of Pharmacy, must be appointed to oversee and enforce these standards.
Read Now